ENV-294

DRUG4 trials

Sponsors

Enveda Therapeutics Inc., Enveda Therapeutics

Conditions

AsthmaAtopic DermatitisAtopic Dermatitis (AD)

Phase 2

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

RecruitingNCT07298395

Enveda TherapeuticsAtopic Dermatitis (AD)

Start: 2025-12-22End: 2026-12-01Target: 60Updated: 2026-07-29

ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults

RecruitingNCT07301255

Enveda TherapeuticsAsthma

Start: 2026-01-09End: 2027-01-01Target: 50Updated: 2026-07-29

A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

RecruitingNCT07643766

Enveda TherapeuticsAtopic Dermatitis

Start: 2026-06-29End: 2028-05-01Target: 200Updated: 2026-08-06

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis

Not yet recruitingCTIS2026-526184-38-00

Enveda Therapeutics Inc.Atopic Dermatitis

Target: 12Updated: 2026-09-10